CN109125736B - 非天然鹅膏毒肽类抗体偶联物 - Google Patents
非天然鹅膏毒肽类抗体偶联物 Download PDFInfo
- Publication number
- CN109125736B CN109125736B CN201810946321.9A CN201810946321A CN109125736B CN 109125736 B CN109125736 B CN 109125736B CN 201810946321 A CN201810946321 A CN 201810946321A CN 109125736 B CN109125736 B CN 109125736B
- Authority
- CN
- China
- Prior art keywords
- compound
- resisting medicine
- synthesis
- cancer
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
- A61K47/6831—Fungal toxins, e.g. alpha sarcine, mitogillin, zinniol or restrictocin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111502809.0A CN114191564A (zh) | 2017-08-18 | 2018-08-18 | 一种非天然鹅膏毒肽类抗体偶联物 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2017107102936 | 2017-08-18 | ||
CN201710710293 | 2017-08-18 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111502809.0A Division CN114191564A (zh) | 2017-08-18 | 2018-08-18 | 一种非天然鹅膏毒肽类抗体偶联物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN109125736A CN109125736A (zh) | 2019-01-04 |
CN109125736B true CN109125736B (zh) | 2022-01-04 |
Family
ID=64790218
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111502809.0A Pending CN114191564A (zh) | 2017-08-18 | 2018-08-18 | 一种非天然鹅膏毒肽类抗体偶联物 |
CN201810946321.9A Active CN109125736B (zh) | 2017-08-18 | 2018-08-18 | 非天然鹅膏毒肽类抗体偶联物 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111502809.0A Pending CN114191564A (zh) | 2017-08-18 | 2018-08-18 | 一种非天然鹅膏毒肽类抗体偶联物 |
Country Status (8)
Country | Link |
---|---|
US (1) | US20210030887A1 (zh) |
EP (1) | EP3738608A4 (zh) |
JP (1) | JP7335260B2 (zh) |
CN (2) | CN114191564A (zh) |
AU (1) | AU2018317611B2 (zh) |
CA (1) | CA3095071A1 (zh) |
SG (1) | SG11202008284XA (zh) |
WO (1) | WO2019034175A1 (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020155017A1 (en) * | 2019-01-31 | 2020-08-06 | Hangzhou Dac Biotech Co., Ltd | A conjugate of an amanita toxin with branched linkers |
CA3138405A1 (en) * | 2019-05-23 | 2020-11-26 | Heidelberg Pharma Research Gmbh | Antibody drug conjugates with cleavable linkers |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102448494A (zh) * | 2009-02-13 | 2012-05-09 | 免疫医疗公司 | 具有胞内可裂解的键的免疫共轭物 |
CN103442736A (zh) * | 2011-03-10 | 2013-12-11 | 海德堡医药有限责任公司 | 具有改良键合的鹅膏毒素共轭物 |
CN104470891A (zh) * | 2012-07-13 | 2015-03-25 | 海德堡医药有限责任公司 | 用于合成鹅膏毒素结构单元及鹅膏毒素的方法 |
CA3016172A1 (en) * | 2016-04-20 | 2017-03-23 | Hangzhou Dac Biotech Co., Ltd | Derivatives of amanita toxins and their conjugation to a cell binding molecule |
WO2017089607A1 (en) * | 2015-11-27 | 2017-06-01 | Heidelberg Pharma Gmbh | Derivatives of gamma-amanitin |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2015782A4 (en) * | 2006-04-12 | 2010-04-07 | Crosslink Genetics Corp | COMPOSITIONS AND METHODS FOR MODULATING GENE EXPRESSION |
LT3192529T (lt) * | 2009-04-08 | 2020-06-25 | Faulstich, Heinz, Dr. | Amatoksinu užtaisyti terapiniai su ląstelės paviršiumi susirišantys komponentai, sukonstruoti navikų terapijai |
KR20110140124A (ko) * | 2009-04-08 | 2011-12-30 | 하인즈 파울스티히 | 암치료용 아미톡신-활성 표적 결합 부위 |
EP2436398B1 (en) * | 2010-09-30 | 2013-01-23 | Heidelberg Pharma GmbH | Amatoxin-conjugates with improved linkers |
EP2774624A1 (en) * | 2013-03-04 | 2014-09-10 | Heidelberg Pharma GmbH | Amatoxin derivatives |
JP6321687B2 (ja) * | 2014-03-10 | 2018-05-09 | ハイデルベルク ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング | アマトキシン誘導体 |
EP3268047B9 (en) * | 2015-03-09 | 2024-01-10 | Heidelberg Pharma Research GmbH | Amatoxin-antibody conjugates |
EP3222292A1 (en) * | 2016-03-03 | 2017-09-27 | Heidelberg Pharma GmbH | Amanitin conjugates |
KR102459469B1 (ko) * | 2016-11-14 | 2022-10-26 | 항저우 디에이씨 바이오테크 씨오, 엘티디 | 결합 링커, 그러한 결합 링커를 함유하는 세포 결합 분자-약물 결합체, 링커를 갖는 그러한 결합체의 제조 및 사용 |
WO2018115466A1 (en) * | 2016-12-23 | 2018-06-28 | Heidelberg Pharma Research Gmbh | Amanitin antibody conjugates |
AU2018314668B2 (en) * | 2017-08-07 | 2022-06-02 | Heidelberg Pharma Research Gmbh | Novel method for synthesizing amanitins |
-
2018
- 2018-08-18 WO PCT/CN2018/101213 patent/WO2019034175A1/zh unknown
- 2018-08-18 AU AU2018317611A patent/AU2018317611B2/en active Active
- 2018-08-18 CN CN202111502809.0A patent/CN114191564A/zh active Pending
- 2018-08-18 JP JP2020551476A patent/JP7335260B2/ja active Active
- 2018-08-18 US US16/975,406 patent/US20210030887A1/en active Pending
- 2018-08-18 CA CA3095071A patent/CA3095071A1/en active Pending
- 2018-08-18 EP EP18846261.8A patent/EP3738608A4/en active Pending
- 2018-08-18 SG SG11202008284XA patent/SG11202008284XA/en unknown
- 2018-08-18 CN CN201810946321.9A patent/CN109125736B/zh active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102448494A (zh) * | 2009-02-13 | 2012-05-09 | 免疫医疗公司 | 具有胞内可裂解的键的免疫共轭物 |
CN103442736A (zh) * | 2011-03-10 | 2013-12-11 | 海德堡医药有限责任公司 | 具有改良键合的鹅膏毒素共轭物 |
CN104470891A (zh) * | 2012-07-13 | 2015-03-25 | 海德堡医药有限责任公司 | 用于合成鹅膏毒素结构单元及鹅膏毒素的方法 |
WO2017089607A1 (en) * | 2015-11-27 | 2017-06-01 | Heidelberg Pharma Gmbh | Derivatives of gamma-amanitin |
CA3016172A1 (en) * | 2016-04-20 | 2017-03-23 | Hangzhou Dac Biotech Co., Ltd | Derivatives of amanita toxins and their conjugation to a cell binding molecule |
Also Published As
Publication number | Publication date |
---|---|
JP7335260B2 (ja) | 2023-08-29 |
CN114191564A (zh) | 2022-03-18 |
JP2021519751A (ja) | 2021-08-12 |
US20210030887A1 (en) | 2021-02-04 |
SG11202008284XA (en) | 2020-09-29 |
AU2018317611B2 (en) | 2022-03-10 |
CA3095071A1 (en) | 2019-02-21 |
CN109125736A (zh) | 2019-01-04 |
EP3738608A4 (en) | 2021-12-08 |
EP3738608A1 (en) | 2020-11-18 |
WO2019034175A1 (zh) | 2019-02-21 |
AU2018317611A1 (en) | 2020-12-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2020259258A1 (zh) | 一种抗体偶联药物、其中间体、制备方法及应用 | |
AU2018288029B2 (en) | Antibody-drug conjugate having acidic self-stabilization junction | |
CN109464654B (zh) | 鹅膏毒肽类抗体偶联物 | |
CN111001012A (zh) | 一种亲水碳酸酯型抗体偶联药物 | |
CN113816990B (zh) | 修饰的氨基酸及其在adc中的应用 | |
CN109125736B (zh) | 非天然鹅膏毒肽类抗体偶联物 | |
US11319341B2 (en) | Immune-stimulating soluble doxorubicin-conjugated complex | |
JP2022518601A (ja) | 抗体薬物複合体用薬物リンカーmc-mmafの調製方法及びその中間体 | |
CN114053426B (zh) | 一种双药链接组装单元及双药靶向接头-药物偶联物 | |
CA3039559A1 (en) | Cysteine modified antibody-drug conjugate and preparation method thereof | |
CN110974975A (zh) | 一种快速释放的抗体药物偶联物 | |
CN109232712B (zh) | 一种用于抗体药物偶联物的中间体的制备方法 | |
CN116712563A (zh) | N-卤代烷基取代的喜树碱衍生物的抗体偶联药物 | |
CN116712562A (zh) | N-叠氮烷基取代的喜树碱衍生物的抗体偶联药物 | |
RU2798981C2 (ru) | Конъюгат антитела с аматоксином неприродного типа | |
WO2021077317A1 (zh) | 一种寡肽连接子中间体及其制备方法 | |
RU2809116C2 (ru) | Конъюгат амантина с антителом | |
RU2793125C2 (ru) | Конъюгат антитело-лекарственное средство, имеющий кислотный самостабилизирующийся участок соединения | |
CN117298291A (zh) | Fc结合肽偶联物、靶向TROP2的定点偶联ADC及其制备方法和应用 | |
CN111195353A (zh) | 一种美登素类抗体药物偶联物及其应用 | |
WO2024140443A1 (zh) | N-叠氮烷基取代的喜树碱衍生物的抗体偶联药物 | |
KR20190143246A (ko) | 신규한 링커 화합물 및 이를 포함하는 위치 특이적인 항체-약물 결합체 화합물 | |
CN115192732A (zh) | 一种dna毒性二聚体化合物及其偶联物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20210520 Address after: 611130 Chengdu cross strait science and Technology Industry Development Park, Wenjiang District, Chengdu City, Sichuan Province Applicant after: Sichuan Baili Pharm Co.,Ltd. Applicant after: Chengdu duote antibody medicine Co.,Ltd. Address before: 611130 Chengdu cross strait science and Technology Industry Development Park, Wenjiang District, Chengdu City, Sichuan Province Applicant before: Sichuan Baili Pharm Co.,Ltd. |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CP01 | Change in the name or title of a patent holder | ||
CP01 | Change in the name or title of a patent holder |
Address after: 611130 Chengdu cross strait science and Technology Industry Development Park, Wenjiang District, Chengdu City, Sichuan Province Patentee after: SICHUAN BAILI PHARM Co.,Ltd. Patentee after: Chengdu bailidote Biological Pharmaceutical Co.,Ltd. Address before: 611130 Chengdu cross strait science and Technology Industry Development Park, Wenjiang District, Chengdu City, Sichuan Province Patentee before: SICHUAN BAILI PHARM Co.,Ltd. Patentee before: Chengdu duote antibody medicine Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20220824 Address after: 610000 Building 1, No. 161 Baili Road, Chengdu cross strait science and Technology Industrial Development Park, Wenjiang District, Chengdu, Sichuan Patentee after: Chengdu bailidote Biological Pharmaceutical Co.,Ltd. Address before: 611130 Chengdu cross strait science and Technology Industry Development Park, Wenjiang District, Chengdu City, Sichuan Province Patentee before: SICHUAN BAILI PHARM Co.,Ltd. Patentee before: Chengdu bailidote Biological Pharmaceutical Co.,Ltd. |